KalVista CMO RSU Settlement and Sell-to-Cover Transaction Disclosed
Rhea-AI Filing Summary
KalVista Pharmaceuticals insider filing: Chief Medical Officer Audhya Paul K. received 5,000 restricted stock units (RSUs) that vested and settled on 08/22/2025 and represent rights to 5,000 shares. Following that settlement the reporting person beneficially owned 124,841 shares. A subsequent sale of 2,336 shares occurred on 08/25/2025 at a price of $13.42 per share to satisfy tax withholding for the RSU vesting, leaving 122,505 shares beneficially owned. The RSUs vest quarterly at 1/16th of the total and the report shows 55,000 underlying RSUs in total.
Positive
- Transparent disclosure of RSU settlement and sell-to-cover transaction including quantities and price
- Majority retention remains after the tax sale: 122,505 shares beneficially owned
- Clear vesting schedule disclosed: 1/16th of total RSUs vest quarterly
Negative
- Insider sale of 2,336 shares occurred (though disclosed as sell-to-cover for taxes)
- Potential dilution implicit from 55,000 total RSUs outstanding
Insights
TL;DR Insider received and settled RSUs and executed a routine sell-to-cover for taxes; no material change to control.
The Form 4 documents receipt of 5,000 RSUs settled for 5,000 shares and a subsequent tax-driven sale of 2,336 shares at $13.42. The sale is explicitly a sell-to-cover to satisfy withholding and is not presented as a discretionary disposition. Beneficial ownership remains sizable at 122,505 shares after transactions. For investors this is a routine insider liquidity event tied to compensation rather than a signal of material strategic change.
TL;DR Transaction aligns with typical equity-compensation practices and includes clear vesting and tax-withholding disclosure.
The filing discloses standard RSU settlement mechanics: each RSU converts to one share at no consideration, a quarterly vesting cadence of 1/16th, and that the sale on 08/25/2025 was to meet tax withholding. The Form 4 is complete in identifying the nature of the transaction and the reporting person’s role as Chief Medical Officer. No governance concerns are evident from the disclosed items.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 2,336 | $13.42 | $31K |
| Exercise | Restricted Stock Unit | 5,000 | $0.00 | -- |
| Exercise | Common Stock | 5,000 | $0.00 | -- |
Footnotes (1)
- Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. 1/16th of the total number of shares underlying the RSUs shall vest on each quarterly anniversary of the Vesting Commencement Date thereafter, for so long as grantee's Service (as defined in the Plan) does not terminate.
